Abstract 280P
Background
Multiple studies in the past have elaborated the role of different risks stratification scores such as Sokal, Hasford, and Eutos (S.H.E.). These studies either correlated the risk stratification with survival, PFS, CcyR, MMR, or point BCR-ABL at different time intervals post-TKI. However, as we understand, all patients do not have a similar disease burden at the initiation of TKI. Also, using cut off level for different age group, gender, and disease burdens is an oversimplification of the disease remission criteria. There are very few studies on the rate (velocity) of the fall of BCR-ABL. The aim of this study was to compare the efficacy of various prognostic score in predicting the fall in BCR ABL over two years.
Methods
This is a prospective observational study comprising 653 (sample size predicted: 300) patients managed at a tertiary care center in north India based on a uniform treatment and evaluation protocol (Generic Imatinib 400 mg OD and three monthly RQ-PCR-BCR/ABL-IS). Statistics were done using Python-13.
Results
The median age of the study population was 43 years (16-87). On comparing the three risk groups of Sokal, the high-risk patients had the least fall in BCR-ABL at any time point up to 2 years post intiation of TKI. Whereas, there was no difference between low and intermediate risk. The difference in the three groups was not statistically significant. There was also no statistically significant difference in the rate of fall of BCR/ABL in the three risk groups of Hasford. The two risk groups of Eutos score had a significant difference in the rate of fall of BCR/ABL, the high risk having a lower rate in comparison to low risk.
Conclusions
Of the three scoring systems, the EUTOS score outperforms as a prognostic model using rate of fall of BCR-ABL in newly diagnosed CML-CP patients upto two years on Generic Imatinib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NA.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract